18-Fluorothymidine positron emission tomography (18-FLT PET/CT) to assess tumour proliferation during radical radiotherapy

Research study of 18-FLT (18F-3'-fluoro-3-deoxy-L-thymidine) positron emission tomography (PET/CT) sequential imaging to quantify tumour proliferation during radical radiotherapy in patients with non-small cell lung cancers and head and neck cancers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN97398362

Enrollment

Registered

2010-07-27

Start date

2010-06-17

Completion date

Unknown

Last updated

2017-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: National Cancer Research Network

Interventions

1. Arterial line: Arterial line placed in the radial artery by experienced Intensive Care Unit physicians. Blood tests taken from this arterial line. 2. Biopsy material: Ultrasound guided fine needle

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. About to undergo radical radiotherapy for one of the following: 1.1. Non-small cell lung cancer with staging between I - III and either the primary tumour or an involved lymph node being greater than 3 cm in maximum dimension 1.2. Squamous cell carcinoma of the head and neck region with staging between II - IVA and either the primary tumour or an involved lymph node being greater than 3 cm in maximum dimension 2. Over 18 years of age, either sex 3. Able to understand consent form 4. Fit for extra incovenience of longer stays in hospital on days of scans 5. Receiving chemotherapy concurrently with radiotherapy

Exclusion criteria

Exclusion criteria: 1. Patient unfit to attend extra scanning visits 2. Tumour criteria not met 3. Clotting disorder for head and neck group 4. Severe claustrophobia or inability to tolerate PET/CT 5. Unable to provide written consent 6. Pregnant or breastfeeding women 7. Subjects taking nucleoside analog medications such as those used as antiretroviral agents

Design outcomes

Primary

Measure	Time frame
Stability of tumour FLT spatial uptake pattern throughout treatment, measured during treatment and 3 months afterwards.	—

Secondary

Measure	Time frame
1. Average time-course of overall tumour FLT uptake 2. Patient-to-patient differences in FLT uptake time-course 3. Characterisation of typical spatial pattern of tumour FLT uptake 4. Patient-to-patient variability in tumour FLT spatial uptake patterns 5. Relationships between CK-18Asp396 levels in blood and changes in tumour FLT uptake between scans 6. Comparison of FLT kinetics with SUV values All the secondary outcomes will be measured at baseline, during radiotherapy and at 3 months follow up.	—

Measure

Time frame

1. Average time-course of overall tumour FLT uptake 2. Patient-to-patient differences in FLT uptake time-course 3. Characterisation of typical spatial pattern of tumour FLT uptake 4. Patient-to-patient variability in tumour FLT spatial uptake patterns 5. Relationships between CK-18Asp396 levels in blood and changes in tumour FLT uptake between scans 6. Comparison of FLT kinetics with SUV values All the secondary outcomes will be measured at baseline, during radiotherapy and at 3 months follow up.

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026